| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | Valamehr Bahram | 664.7K | $801.0K | -5,190 |
| Other | TAHL CINDY | 487.1K | $586.9K | -10,589 |
| Other | 397.7K | $479.2K | - | |
| CEO | 334.9K | $403.6K | - | |
| ? | ABERNETHY MATT | 110.0K | $132.6K | - |
| CFO | Adawi Kamal | 100.0K | $120.5K | - |
| CFO | 75.0K | $90.4K | - | |
| ? | 55.0K | $66.3K | - | |
| ? | 55.0K | $66.3K | - | |
| ? | Xu Yuan | 55.0K | $66.3K | - |
| ? | Mozaffarian Neelufar | 55.0K | $66.3K | - |
| ? | RASTETTER WILLIAM H | 55.0K | $66.3K | - |
| ? | MENDLEIN JOHN | 55.0K | $66.3K | - |
| ? | Jooss Karin | 55.0K | $66.3K | - |
| ? | EPSTEIN ROBERT S | 55.0K | $66.3K | - |
| ? | Agarwal Shefali | 55.0K | $66.3K | - |
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| 2022-06-03 | MENDLEIN JOHN | - | Sell | 1,364 | $22.79 | $31,085.56 | -0.9% | → |
| 2022-06-03 | Jooss Karin | - | Sell | 1,483 | $22.82 | $33,842.06 | -55.3% | → |
| 2022-06-03 | Agarwal Shefali | - | Sell | 807 | $22.80 | $18,399.60 | -30.1% | → |
| 2022-06-03 | COUGHLIN TIMOTHY | - | Sell | 1,439 | $22.81 | $32,823.59 | -2.4% | → |
| 2022-06-03 | HERSHBERG ROBERT | - | Sell | 672 | $22.75 | $15,288.00 | -25.1% | → |
| 2022-06-01 | TAHL CINDY | General Counsel and Secretary | Sale+OE | 25,000 | $22.96 | $574,000.00 | -11.7% | → |
| 2022-04-22 | Wolchko J Scott | President and CEO | Sale+OE | 40,000 | $34.89 | $1,395,791.69 | -1.5% | → |
| 2022-04-19 | Chu Yu-Waye | Chief Medical Officer | Sell | 4,062 | $35.37 | $143,672.94 | -2.6% | → |
| 2022-04-01 | TAHL CINDY | General Counsel and Secretary | Sale+OE | 25,000 | $38.85 | $971,250.00 | -11.7% | → |
| 2022-03-14 | Valamehr Bahram | Chief R&D Officer | Sale+OE | 25,000 | $31.07 | $776,732.85 | -2.7% | → |
| 2022-03-10 | MENDLEIN JOHN | - | Sale+OE | 31,562 | $35.02 | $1,105,200.01 | -8.7% | → |
| 2022-01-21 | Wolchko J Scott | President and CEO | Sale+OE | 40,000 | $39.66 | $1,586,500.00 | -4.4% | → |
| 2022-01-11 | Dulac Edward J III | Chief Financial Officer | Sell | 1,770 | $48.45 | $85,757.40 | -0.8% | → |
| 2022-01-11 | Wolchko J Scott | President and CEO | Sell | 14,566 | $48.68 | $709,026.83 | -1.7% | → |
| 2022-01-11 | Chu Yu-Waye | Senior VP Clinical Development | Sell | 3,965 | $48.51 | $192,340.48 | -1.6% | → |
| 2022-01-11 | Valamehr Bahram | Chief R&D Officer | Sell | 4,570 | $48.50 | $221,655.04 | -1.5% | → |
| 2022-01-11 | TAHL CINDY | General Counsel and Secretary | Sell | 5,419 | $48.53 | $262,974.58 | -1.7% | → |
| 2022-01-10 | Wolchko J Scott | President and CEO | Sell | 34,156 | $46.86 | $1,600,533.66 | -2.5% | → |
| 2022-01-10 | Valamehr Bahram | Chief R&D Officer | Sell | 5,596 | $46.38 | $259,557.52 | -1.8% | → |
| 2022-01-10 | TAHL CINDY | General Counsel and Secretary | Sell | 7,738 | $46.43 | $359,312.60 | -2.3% | → |
| 2022-01-03 | TAHL CINDY | General Counsel and Secretary | Sale+OE | 50,000 | $59.34 | $2,966,852.75 | -6.2% | → |
| 2021-12-20 | Dulac Edward J III | Chief Financial Officer | Sale+OE | 15,977 | $60.00 | $958,620.00 | -12.6% | → |
| 2021-12-13 | Valamehr Bahram | Chief R&D Officer | Sale+OE | 25,000 | $47.66 | $1,191,405.50 | -2.9% | → |